[1]
M. H. . Ahasan, “Comparison of Safety and Efficacy Between Dabigatran and Rivaroxaban in Nonvalvular Atrial Fibrillation in Tertiary Level Hospital”, Univ. Heart J., vol. 18, no. 1, pp. 10–13, Jan. 2022.